Matches in SemOpenAlex for { <https://semopenalex.org/work/W3112175037> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W3112175037 abstract "The problem of cardiovascular diseases is the leading one among the problems of the World Health Organization, thus justifying any attempts to identify both etiological and pathogenetic factors of their formation. At the same time, a special place is occupied by studies of the possibilities of pharmacological correction of the most frequent vascular pathology - atherosclerosis and pathology of the blood composition - hyperlipidemia. From the point of view of the concept of adaptation syndrome, the authors considered these phenomena as maladjustment. In this regard, the purpose of this study was to study the possibility of using a biologically active supplement trerevit against the background of basic treatment of patients with atherosclerosis and impaired blood lipid profile. To achieve this goal, the following methods were used. We examined 32 male patients aged 35 to 50 years with signs of carotid artery sclerosis. All patients received basic therapy with miscleron and aspirin. Patients of the main group, in addition to basic therapy, received trerevit at a dose of 4 tablets / day for 3 months. When using trekrevit in combination with basic drugs, lipid metabolism and indicators of the development of sclerosis of the carotid arteries in patients significantly improved. The results obtained indicate the fact that in patients with atherosclerosis, basic therapy in combination with trerevitis has a high efficiency - almost 85%. In addition, this combination of drugs has organoprotective properties: during treatment, the thickness of the intima-media complex of the carotid arteries decreases, while in some patients it reached normal values. It is concluded that taking trerevit in addition to basic therapy reliably reduces metabolic disturbances in the patient, and also reduces changes in the vascular wall of the carotid arteries. In addition, trekrevit has a previously unknown property - to exert a potentiating effect on the effects of the basic drug miscleron. Finally, trerevit can be included in comprehensive programs as a complementary, compatible with other drugs, to improve the effectiveness of treatment and improve the quality of life of patients." @default.
- W3112175037 created "2020-12-21" @default.
- W3112175037 creator A5068640751 @default.
- W3112175037 creator A5079000332 @default.
- W3112175037 creator A5082025545 @default.
- W3112175037 date "2020-12-04" @default.
- W3112175037 modified "2023-09-26" @default.
- W3112175037 title "ANTIATHEROSCLEROTIC AND HYPOLIPIDEMIC EFFECTS OF TREKREVIT" @default.
- W3112175037 doi "https://doi.org/10.26787/nydha-2618-8783-2020-5-4-60-66" @default.
- W3112175037 hasPublicationYear "2020" @default.
- W3112175037 type Work @default.
- W3112175037 sameAs 3112175037 @default.
- W3112175037 citedByCount "0" @default.
- W3112175037 crossrefType "journal-article" @default.
- W3112175037 hasAuthorship W3112175037A5068640751 @default.
- W3112175037 hasAuthorship W3112175037A5079000332 @default.
- W3112175037 hasAuthorship W3112175037A5082025545 @default.
- W3112175037 hasConcept C126322002 @default.
- W3112175037 hasConcept C134018914 @default.
- W3112175037 hasConcept C137627325 @default.
- W3112175037 hasConcept C139572402 @default.
- W3112175037 hasConcept C164705383 @default.
- W3112175037 hasConcept C203014093 @default.
- W3112175037 hasConcept C2777628954 @default.
- W3112175037 hasConcept C2778163477 @default.
- W3112175037 hasConcept C2779091943 @default.
- W3112175037 hasConcept C2780640218 @default.
- W3112175037 hasConcept C2987047532 @default.
- W3112175037 hasConcept C500440147 @default.
- W3112175037 hasConcept C555293320 @default.
- W3112175037 hasConcept C71924100 @default.
- W3112175037 hasConceptScore W3112175037C126322002 @default.
- W3112175037 hasConceptScore W3112175037C134018914 @default.
- W3112175037 hasConceptScore W3112175037C137627325 @default.
- W3112175037 hasConceptScore W3112175037C139572402 @default.
- W3112175037 hasConceptScore W3112175037C164705383 @default.
- W3112175037 hasConceptScore W3112175037C203014093 @default.
- W3112175037 hasConceptScore W3112175037C2777628954 @default.
- W3112175037 hasConceptScore W3112175037C2778163477 @default.
- W3112175037 hasConceptScore W3112175037C2779091943 @default.
- W3112175037 hasConceptScore W3112175037C2780640218 @default.
- W3112175037 hasConceptScore W3112175037C2987047532 @default.
- W3112175037 hasConceptScore W3112175037C500440147 @default.
- W3112175037 hasConceptScore W3112175037C555293320 @default.
- W3112175037 hasConceptScore W3112175037C71924100 @default.
- W3112175037 hasLocation W31121750371 @default.
- W3112175037 hasOpenAccess W3112175037 @default.
- W3112175037 hasPrimaryLocation W31121750371 @default.
- W3112175037 hasRelatedWork W101161441 @default.
- W3112175037 hasRelatedWork W113818359 @default.
- W3112175037 hasRelatedWork W139814500 @default.
- W3112175037 hasRelatedWork W151052042 @default.
- W3112175037 hasRelatedWork W1784574150 @default.
- W3112175037 hasRelatedWork W1851800008 @default.
- W3112175037 hasRelatedWork W201032933 @default.
- W3112175037 hasRelatedWork W323827438 @default.
- W3112175037 hasRelatedWork W1798907679 @default.
- W3112175037 hasRelatedWork W954440824 @default.
- W3112175037 isParatext "false" @default.
- W3112175037 isRetracted "false" @default.
- W3112175037 magId "3112175037" @default.
- W3112175037 workType "article" @default.